Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (DFPH) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to $144.6 million.

  • Oncology Institute's Operating Expenses rose 2713.22% to $144.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $502.1 million, marking a year-over-year increase of 1350.2%. This contributed to the annual value of $453.5 million for FY2024, which is 1302.73% up from last year.
  • Per Oncology Institute's latest filing, its Operating Expenses stood at $144.6 million for Q3 2025, which was up 2713.22% from $131.0 million recorded in Q2 2025.
  • Oncology Institute's Operating Expenses' 5-year high stood at $144.6 million during Q3 2025, with a 5-year trough of $50.3 million in Q1 2021.
  • Its 5-year average for Operating Expenses is $96.2 million, with a median of $96.5 million in 2022.
  • As far as peak fluctuations go, Oncology Institute's Operating Expenses soared by 5661181.5% in 2021, and later soared by 149.06% in 2025.
  • Over the past 5 years, Oncology Institute's Operating Expenses (Quarter) stood at $93.1 million in 2021, then increased by 3.62% to $96.5 million in 2022, then increased by 4.74% to $101.1 million in 2023, then increased by 11.0% to $112.2 million in 2024, then rose by 28.9% to $144.6 million in 2025.
  • Its Operating Expenses was $144.6 million in Q3 2025, compared to $131.0 million in Q2 2025 and $114.3 million in Q1 2025.